8月21日，Twist Bioscience盘中上涨5.07%，报143.245美元/股，成交额1.0亿美元，延续前一交易日大涨逾22%的强势表现。
消息面上，公司于8月20日披露被Anthropic选为多臂AI蛋白质设计项目的独立评估机构，负责大规模快速生产AI设计的蛋白质并测试其结合能力。Anthropic利用Claude Opus 4.8和Mythos Preview针对15个靶点开展蛋白质设计实验，Twist Bioscience作为外部评估方的角色进一步夯实了其在AI制药产业链中DNA合成及蛋白质生产环节的核心供应商地位。基本面上，公司此前发布的Q3营收1.184亿美元超预期，Q4指引1.23亿至1.24亿美元亦大幅高于市场预估的1.174亿美元，业绩持续改善叠加AI制药商业化落地提速，共同支撑股价高位运行。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.